References
- LawesCMVander HoornSRodgersAInternational Society of HypertensionGlobal burden of blood-pressure-related disease, 2001Lancet20083711513151818456100
- GavrasHUpdate on the clinical pharmacology of candesartan cilexetilAm J Hypertens20001325S30S10678285
- YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581547155918378520
- Van LiefdeIVauquelinGSartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonismMol Cell Endocrinol200930223724318620019
- FabianiMEDinhDTNassisLCasleyDJJohnstonCIIn vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartanAm J Hypertens2000131005101310981551
- OjimaMInadaYShiboutaYCandesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptorEur J Pharmacol19973191371469030909
- KjeldsenSEStalhammarJHasvoldPBodegardJOlssonURussellDEffects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertensionJ Hum Hypertens20102426327319890371
- HenrikssonMRussellDBodegardJHealth-care costs of losartan and candesartan in the primary treatment of hypertensionJ Hum Hypertens20102513013620376078
- RussellDStålhammarJBodegardJHasvoldPThuressonMKjeldsenSECardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartanJ Clin Hypertens201113189197
- Eklind-CervenkaMBensonLDahlstromUEdnerMRosenqvistMLundLHAssociation of candesartan vs losartan with all-cause mortality in patients with heart failureJAMA201130517518221224459
- LFNLäkemedelsförmånsnämndens allmänna råd om ekonomiska utvärderingarLFNAR20032 Available from: http://www.tlv.seAccessed September 20, 2012
- BriggsAHClaxtonKSculpherMJDecision Modelling for Health Economic EvaluationOxford, UKOxford University Press2006
- Statistics SwedenLife table (Livslängdstabell) 2005–2009 Available from: http://www.scb.seAccessed September 20, 2012
- Board of Health and WelfareStatistics database, cause of death statistics Available from: http://www.socialstyrelsen.seAccessed September 20, 2012
- BurströmKRehnbergKHälsorelaterad livskvalitet i Stockholms län 2002. Resultat per åldersgrupp och kön, utbildningsnivå, födelseland samt sysselsättningsgrupp – en befolkningsundersökning med EQ-5D. Rapport20061Centrum för folkhälsa, Enheten förSocialmedicin och Hälsoekonomi, Stockholms läns landsting
- SigvantBHenrikssonMLundinFWahlbergEAsymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?Eur J Cardiovasc Prev Rehabil20111825426121450673
- AlehagenURahmqvistMPaulssonTLevinLAQuality-adjusted life year weights among elderly patients with heart failureEur J Heart Fail2008101033103918760669
- ReynoldsMRZimetbaumPJosephsonMEEllisEDanilovTCohenDJCost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillationCirc Arrhythm Electrophysiol2009236236919808491
- ClarkePGrayAHolmanREstimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)Med Decis Making20022234034912150599
- LindgrenPKahanTPoulterNUtility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudyEur J Health Econ20078253017165074
- AgvallBBorgquistLFoldeviMDahlstromUCost of heart failure in Swedish primary healthcareScand J Prim Health Care20052322723216272071
- DavidssonTLevinLKostnaden för förmaksflimmer i ÖstergötlandCMT reportLinköping, SwedenCentre for Medical Technology Assessment, Linköping University2006
- HenrikssonMPalmerSChenRAssessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgeryBMJ2010340b560620085988
- GhatnekarOPerssonUGladerELTerentACost of stroke in Sweden: an incidence estimateInt J Technol Assess Health Care20042037538015446769